<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055843</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0273</org_study_id>
    <secondary_id>NCI-2021-05282</secondary_id>
    <secondary_id>2021-0273</secondary_id>
    <nct_id>NCT05055843</nct_id>
  </id_info>
  <brief_title>Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer</brief_title>
  <official_title>Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Prostate Cancer Without an Endorectal Coil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies examines a 3D magnetic resonance imaging (MRI) compared to&#xD;
      standard MRI imaging techniques in screening patients with prostate cancer. Diagnostic&#xD;
      procedures, such as MRI, may help find and diagnose prostate cancer. Computer systems that&#xD;
      allow doctors to create a 3-dimensional (3-D) picture of the tumor may help in planning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine whether the image quality of the novel 3-dimensional (3D) T2-weighted imaging&#xD;
      (T2W) synthetic imaging technique without endorectal coil is comparable to the 2-dimensional&#xD;
      (2D) T2W imaging technique without endorectal coil.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the qualitative diagnostic quality of the T2W images provided by the novel 3D&#xD;
      technique, as determined by subjective scoring by experienced readers.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To investigate the feasibility of novel 3D synthetic imaging and multi-spin parameter&#xD;
      mapping technique of prostate for the detection of clinically significant prostate cancer&#xD;
      (csPCa).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo 3D MRI imaging over 15 minutes with standard of care MRI or at a separate&#xD;
      time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in the image quality of the novel dimensions</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Comparing the 2-dimensional (2D) T2W imaging technique without endorectal coil.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Screening (3D MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 3D MRI imaging over 15 minutes with standard of care MRI or at a separate time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo 3D MRI</description>
    <arm_group_label>Screening (3D MRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, age &gt;= 18&#xD;
&#xD;
          -  Untreated, biopsy-proven with intermediate and high-risk adenocarcinoma of the&#xD;
             prostate&#xD;
&#xD;
          -  Patient is being considered for curative-intent treatment with radical prostatectomy&#xD;
&#xD;
          -  Patient has provided written informed consent for participation in this trial&#xD;
&#xD;
          -  Patient should be eligible for scanning on a 3T magnet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Low-risk adenocarcinoma of prostate&#xD;
&#xD;
          -  Any prior therapy for prostate cancer&#xD;
&#xD;
          -  A history of other active malignancy within the last 2 years&#xD;
&#xD;
          -  Prostate cancer with significant sarcomatoid, spindle cell, or neuroendocrine small&#xD;
             cell components&#xD;
&#xD;
          -  Cardiac pacemaker&#xD;
&#xD;
          -  Orthopedic hardware in the pelvis and spine&#xD;
&#xD;
          -  Claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tharakeswara Bathala</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tharakeswara Bathala</last_name>
      <phone>713-792-2533</phone>
      <email>tkbathala@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Tharakeswara Bathala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

